2,807
Views
21
CrossRef citations to date
0
Altmetric
Clinical Study

Incidence of and risk factors for post-parathyroidectomy hungry bone syndrome in patients with secondary hyperparathyroidism

ORCID Icon, , , , &
Pages 1118-1126 | Received 10 Jun 2020, Accepted 19 Oct 2020, Published online: 03 Nov 2020

References

  • Jofré R, López Gómez JM, Menárguez J, et al. Parathyroidectomy: whom and when? Kidney Int Suppl. 2003;63:S97–S100.
  • Jamal SA, Miller PD. Secondary and tertiary hyperparathyroidism. J Clin Densitom. 2013;16(1):64–68.
  • Okada M, Tominaga Y, Ichimori T, et al. Surgical outcomes of parathyroidectomy for secondary hyperparathyroidism resistant to calcimimetic treatment: a retrospective single-center cohort study. Ther Apher Dial. 2020;24:1–9.
  • Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what's changed and why it matters . Kidney Int. 2017;92(1):26–36.
  • Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6):952–961.
  • Trombetti A, Stoermann C, Robert JH, et al. Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism. World J Surg. 2007;31(5):1014–1021.
  • Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66(5):2010–2016.
  • Costa-Hong V, Jorgetti V, Gowdak LHW, et al. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery. 2007;142(5):699–703.
  • Assumpção LR, de Paula Ramos I, Nunes da Cunha G, et al. Refractory secondary hyperparathyroidism in waiting list for parathyroidectomy: who we should operate first in a quaternary hospital in Brazil regarding survival. Ren Fail. 2019;41(1):183–189.
  • Rudser KD, de Boer IH, Dooley A, et al. Fracture risk after parathyroidectomy among chronic hemodialysis patients. JASN. 2007;18(8):2401–2407.
  • Jain N, Reilly RF. Hungry bone syndrome. Curr Opin Nephrol Hypertens. 2017;26(4):250–255.
  • Goldfarb M, Gondek SS, Lim SM, et al. Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin. World J Surg. 2012;36(6):1314–1319.
  • Latus J, Roesel M, Fritz P, et al. Incidence of and risk factors for hungry bone syndrome in 84 patients with secondary hyperparathyroidism. Int J Nephrol Renov Dis. 2013;6:131–137.
  • Florescu MC, Islam KM, Plumb TJ, et al. Calcium supplementation after parathyroidectomy in dialysis and renal transplant patients. Int J Nephrol Renov Dis. 2014;7:183–190.
  • Ge Y, Yang G, Wang N, et al. Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Int Urol Nephrol. 2019;51(8):1443–1449.
  • Ho L-Y, Wong P-N, Sin H-K, et al. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2017;18(1):12.
  • Torer N, Torun D, Torer N, et al. Predictors of early postoperative hypocalcemia in hemodialysis patients with secondary hyperparathyroidism. Transplant Proc. 2009;41(9):3642–3646.
  • Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg. 2004;70:114–119.
  • National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S201.
  • Freriks K, Hermus ARMM, de Sévaux RGL, et al. Usefulness of intraoperative parathyroid hormone measurements in patients with renal hyperparathyroidism. Head Neck. 2010;32(10):1328–1335.
  • Witteveen JE, van Thiel S, Romijn JA, et al. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45–53.
  • Cruz DN, Perazella MA. Biochemical aberrations in a dialysis patient following parathyroidectomy. Am J Kidney Dis. 1997;29(5):759–762.
  • Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med. 1988;84(4):654–660.
  • Stefanova D, Ullmann TM, Limberg J, et al. Risk factors for prolonged length of stay and readmission after parathyroidectomy for renal secondary hyperparathyroidism. World J Surg. 2020;44(11):3751–3760.
  • Falko JM, Bush CA, Tzagournis M, et al. Case report. Congestive heart failure complicating the hungry bone syndrome. Am J Med Sci. 1976;271(1):85–89.
  • Shinoda T, Aizawa T, Shirota T, et al. Exacerbation of latent heart failure by mild hypocalcemia after parathyroidectomy in a long-term hemodialysis patient. Nephron. 1992;60(4):482–486.
  • Wang M, Chen B, Zou X, et al. A nomogram to predict hungry bone syndrome after parathyroidectomy in patients with secondary hyperparathyroidism. J Surg Res. 2020;255:33–41.
  • Viaene L, Evenepoel P, Bammens B, et al. Calcium requirements after parathyroidectomy in patients with refractory secondary hyperparathyroidism. Nephron Clin Pract. 2008;110(2):c80–c85.
  • Farese S. [The hungry bone syndrome-an update]. Ther Umsch. 2007;64(5):277–280.
  • Erbil Y, Bozbora A, Ozbey N, et al. Predictive value of age and serum parathormone and vitamin d3 levels for postoperative hypocalcemia after total thyroidectomy for nontoxic multinodular goiter. Arch Surg. 2007;142(12):1182–1187.
  • Liu S, Zhu W, Li S, et al. The effect of bovine parathyroid hormone withdrawal on MC3T3-E1 cell proliferation and phosphorus metabolism. PLoS One. 2015;10(3):e0120402.
  • Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol. 2009;20(7):1453–1464.
  • Nigwekar SU, Bhan I, Turchin A, et al. Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol. 2013;37(4):325–332.
  • Cheng S-P, Liu C-L, Chen H-H, et al. Prolonged hospital stay after parathyroidectomy for secondary hyperparathyroidism. World J Surg. 2009;33(1):72–79.
  • Haarhaus M, Monier-Faugere M-C, Magnusson P, et al. Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study. Am J Kidney Dis. 2015;66(1):99–105.
  • Ohishi M, Schipani E. PTH and stem cells. J Endocrinol Invest. 2011;34(7):552–556.
  • Nigwekar SU, Tamez H, Thadhani RI. Vitamin D and chronic kidney disease-mineral bone disease (CKD-MBD). Bonekey Rep. 2014;3:498.
  • Prié D, Friedlander G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23/Klotho system. Clin J Am Soc Nephrol. 2010;5(9):1717–1722.
  • Akeno N, Saikatsu S, Kawane T, et al. Mouse vitamin D-24-hydroxylase: molecular cloning, tissue distribution, and transcriptional regulation by 1alpha,25-dihydroxyvitamin D3. Endocrinology. 1997;138(6):2233–2240.
  • Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17(5):1305–1315.
  • Denda M, Finch J, Brown AJ, et al. 1,25-dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int. 1996;50(1):34–39.
  • Carlson D. Parathyroid pathology: hyperparathyroidism and parathyroid tumors. Arch Pathol Lab Med. 2010;134(11):1639–1644.
  • DeLellis RA. Parathyroid tumors and related disorders. Mod Pathol. 2011;24(S2):S78–S93.
  • Kebebew E, Duh Q-Y, Clark OH. Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy. Arch Surg. 2004;139(9):974–977.
  • Zhang Y, Lu Y, Feng S, et al. Evaluation of laboratory parameters and symptoms after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Ren Fail. 2019;41(1):921–929.
  • Fülöp T, Koch CA, Farah Musa AR, et al. Targeted surgical parathyroidectomy in end-stage renal disease patients and long-term metabolic control: a single-center experience in the current era. Hemodial Int. 2018;22(3):394–404.
  • Arnold A, Brown MF, Ureña P, et al. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995;95(5):2047–2053.
  • Tominaga Y, Kohara S, Namii Y, et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg. 1996;20(7):744–750.
  • Fukuda N, Tanaka H, Tominaga Y, et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92(3):1436–1443.